Target identification and validation form the cornerstone of successful radiopharmaceutical development, ensuring that a chosen molecular target is not only biologically relevant but also amenable to selective ligand binding and effective radionuclide delivery. Protheragen offers end-to-end target identification and validation services tailored to the unique demands of radiopharmaceutical drug discovery, bridging the gap between exploratory biology and IND-enabling preclinical development.
Radiopharmaceutical development relies on the precise targeting of disease-associated biomarkers—typically receptors, enzymes, or transporters that are overexpressed or uniquely present on malignant cells. The process of target identification involves systematic discovery of such biomarkers through multi-omics profiling, literature mining, and bioinformatics analysis, while target validation rigorously demonstrates that modulation of the target yields a therapeutic or diagnostic benefit. For radiopharmaceuticals specifically, a validated target must exhibit high tumor-to-background expression ratios, minimal off-tissue binding, and accessibility to circulating ligands, as these parameters directly influence imaging contrast and therapeutic index.
Fig 1. Hierarchy of evidence to justify radiopharmaceutical target-driven early-phase combination trial designs. (Kunos, Charles A, et al., 2021)
Once a candidate target is identified, validation proceeds through a tiered hierarchy of evidence: in silico molecular modeling and druggability assessment; in vitro binding assays using recombinant proteins, cell lysates, and tissue homogenates; immunohistochemical screening on tissue microarrays (TMAs) to confirm expression patterns across tumor and normal tissues; and in vivo preclinical imaging and biodistribution studies to evaluate pharmacokinetics, tumor uptake, and normal organ dosimetry. This structured approach de-risks downstream radiochemistry and clinical translation by ensuring that only targets with robust specificity, selectivity, and deliverability advance into lead optimization and radiolabeling campaigns.
The radiopharmaceutical field is undergoing a rapid expansion beyond the established PSMA and SSTR2 paradigms. As of 2026, the clinical pipeline has diversified into a broad portfolio of tumor-associated targets, driven by the need to address resistant disease phenotypes, reduce off-target toxicity, and extend radioligand therapy to solid tumors with limited PSMA or SSTR2 expression. Concurrently, isotope innovation—particularly the shift from beta-emitters (¹⁷⁷Lu) to alpha-emitters (²²⁵Ac, ²¹²Pb) and mixed-emission radionuclides (¹⁶¹Tb)—is reshaping target selection criteria, as shorter path-length emitters demand higher target density and more homogeneous expression to achieve lethal dose deposition.
The table below summarizes the current landscape of clinically validated and emerging radiopharmaceutical targets, their primary indications, ligand classes, and matched diagnostic/therapeutic radionuclide pairs:
| Target | Primary Indications | Ligand Class | Theranostic Radionuclide Pairs | Development Stage |
|---|---|---|---|---|
| PSMA (FOLH1) | Prostate cancer (mCRPC, earlier lines) | Small molecule / antibody | ⁶⁸Ga / ¹⁷⁷Lu, ²²⁵Ac | Marketed (Pluvicto); next-gen ligands in Phase II/III |
| SSTR2 | GEP-NETs, SCLC, Merkel cell carcinoma | Cyclic peptide (DOTA/TATE) | ⁶⁸Ga / ¹⁷⁷Lu, ²²⁵Ac, ¹⁶¹Tb | Marketed (Lutathera); next-gen non-agonists in Phase I/II |
| FAP (FAP-α) | Pan-cancer (sarcoma, gastric, pancreatic, NSCLC) | Small molecule inhibitor (FAPI) | ⁶⁸Ga / ¹⁷⁷Lu, ²²⁵Ac, ²¹²Pb | Phase I/II; ligand optimization ongoing |
| GRPR | Prostate cancer, breast cancer | Bombesin analog | ⁶⁸Ga / ¹⁷⁷Lu | Phase I/II |
| HER2 | Breast cancer, gastric cancer | Affibody / antibody | ⁶⁸Ga / ¹⁷⁷Lu, ²²⁵Ac | Phase I/II |
| DLL3 | SCLC, neuroendocrine tumors | Antibody / peptide | ⁶⁸Ga / ¹⁷⁷Lu, ²²⁵Ac | Phase I |
| B7-H3 | Solid tumors (pediatric and adult) | Antibody / small molecule | ⁶⁸Ga / ¹⁷⁷Lu, ²²⁵Ac | Preclinical / Phase I |
| MC1R | Melanoma | Peptide (VMT01) | ⁶⁸Ga / ²¹²Pb | Phase I/II |
| TROP-2 | Triple-negative breast cancer, NSCLC | Antibody / small molecule | ⁶⁸Ga / ¹⁷⁷Lu | Preclinical |
| Nectin-4 | Urothelial carcinoma, breast cancer | Antibody / peptide | ⁶⁸Ga / ¹⁷⁷Lu | Preclinical |
| LAT1 | Brain tumors, NSCLC | Amino acid analog | ¹⁸F / ¹³¹I | Phase I (imaging) |
| GPC-1 | Pancreatic cancer, HCC | Antibody / peptide | ⁶⁸Ga / ¹⁷⁷Lu | Preclinical |
| EphA2 | Glioblastoma, prostate cancer | Peptide / small molecule | ⁶⁸Ga / ¹⁷⁷Lu | Preclinical |
| uPAR | Pancreatic cancer, colorectal cancer | Peptide (ATF) | ⁶⁸Ga / ¹⁷⁷Lu | Preclinical / Phase I |
| CD46 | Prostate cancer, multiple myeloma | Antibody | ⁶⁸Ga / ²²⁵Ac | Preclinical |
Protheragen provides integrated target identification and validation services specifically designed for radiopharmaceutical programs. Our capabilities span from in silico target discovery and druggability assessment through in vitro binding characterization, immunohistochemical validation on tissue microarrays, and in vivo preclinical imaging and biodistribution studies. By combining computational biology with hands-on radiochemistry and nuclear medicine expertise, we help clients select and validate targets that are not only biologically relevant but also technically viable for ligand-based radionuclide delivery, ensuring a smoother transition from discovery to IND-enabling development.
We employ computational approaches including molecular docking, pharmacophore modeling, machine learning-based target similarity searches, and quantitative structure–activity relationship (QSAR) analysis to identify and prioritize candidate targets. Our in silico workflows evaluate target expression profiles, ligand-binding pocket accessibility, and predicted ADME properties to shortlist targets with the highest probability of successful radiopharmaceutical development.
Using multi-omics data mining, transcriptomic and proteomic profiling, and publicly available cancer databases, we characterize target expression across tumor types, disease stages, and normal tissue compartments. This enables quantitative assessment of tumor-to-background expression ratios—a critical parameter for both diagnostic imaging contrast and therapeutic window.
We perform IHC screening on custom-built TMAs comprising tumor cores, matched normal tissues, and engineered positive/negative controls (antigen knockout or knockdown cell lines). This step confirms target expression patterns, heterogeneity, and staining intensity in a clinically relevant context, providing the first level of evidence for radiopharmaceutical specificity.
Our in vitro suite includes radioligand binding assays on recombinant proteins, cell membrane preparations, and intact cell lines expressing the target of interest. We conduct competition/blocking studies with structurally unrelated compounds to confirm binding specificity, and evaluate internalization kinetics at 37°C versus 4°C to predict receptor-mediated uptake efficiency in vivo.
We perform ex vivo autoradiography on fresh-frozen tissue sections to visualize radiotracer distribution at high spatial resolution. This technique allows initial estimation of specific binding in human or animal tissues while omitting confounding factors such as blood–brain barrier penetration or systemic metabolism, providing a direct readout of target engagement.
Using micro-PET, micro-SPECT, and gamma counting modalities, we evaluate pharmacokinetics, tumor uptake, and normal organ distribution in xenograft, orthotopic, or genetically engineered mouse models. Dynamic imaging combined with arterial blood sampling enables quantitative pharmacodynamic parameter estimation (Bmax/Kd), while blocking and displacement experiments confirm in vivo binding specificity.
We derive preclinical dosimetry estimates by quantifying radionuclide accumulation in tumor and critical normal organs (kidney, liver, bone marrow, salivary glands) across time. These data inform starting dose selection for first-in-human studies and support regulatory submissions by demonstrating a favorable therapeutic index.
For validated targets, we support the design and execution of Phase 0 microdose studies using low-specific-activity or non-radioactive ligand-chelator analogs. These studies provide human pharmacokinetic and biodistribution data that rationalize dose selection, imaging protocols, and patient enrichment strategies for subsequent therapeutic trials.
Ready to advance your radiopharmaceutical program with rigorous target identification and validation? Contact us today to discuss how Protheragen can support your discovery pipeline—from in silico target prioritization through IND-enabling preclinical studies. Our team is prepared to reach out to you with a customized proposal tailored to your specific target, indication, and regulatory pathway. Let us help you build a robust evidence foundation for your next-generation radioligand therapy or diagnostic imaging agent.
Reference